Rapport Therapeutics, Inc. (RAPP)

NASDAQ: RAPP · Real-Time Price · USD

46.98

+1.49 (3.28%)

At close: Aug 10, 2026, 4:00 PM EDT

47.30

+0.32 (0.68%)

After-hours: Aug 10, 2026, 4:18 PM EDT

Rapport Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	20	-	-	-
Revenue Growth	-	-	-	-
Gross Profit	20	-	-	-
Selling, General & Admin	36.85	30.31	22.12	8.18
Research & Development	136.67	94.79	60.94	28
Total Operating Expenses	173.52	125.1	83.06	36.18
Operating Income	-153.52	-125.1	-83.06	-36.18
Interest Income	16.36	13.62	12.14	2.53
Other Non-Operating Income (Expense)	-	-	-7.39	-1.12
Total Non-Operating Income (Expense)	16.36	13.62	4.75	1.4
Pretax Income	-137.16	-111.48	-78.31	-34.78
Provision for Income Taxes	-	-	-	0.01
Net Income	-137.16	-111.48	-78.31	-34.79
Net Income to Common	-137.16	-111.48	-78.31	-34.79
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	45	39	21	2
Shares Outstanding (Diluted)	45	39	21	2
Shares Change	27.72%	87.74%	1277.25%	-
EPS (Basic)	-3.04	-2.86	-3.78	-23.10
EPS (Diluted)	-3.04	-2.86	-3.78	-23.10
EPS Growth	-	-	-	-
Free Cash Flow	-97.15	-88.09	-67.23	-28.82
Free Cash Flow Growth	-	-	-	-
Free Cash Flow Per Share	-2.16	-2.26	-3.24	-19.14
Gross Margin	100.00%	-	-	-
Operating Margin	-767.58%	-	-	-
Profit Margin	-685.80%	-	-	-
FCF Margin	-485.75%	-	-	-
EBITDA	-152.56	-124.08	-82.22	-36.07
EBITDA Margin	-762.78%	-	-	-
EBIT	-153.52	-125.1	-83.06	-36.18
EBIT Margin	-767.58%	-	-	-
Effective Tax Rate	-	0.00%	0.00%	-0.03%

SEC Filings: 10-K · 10-Q